ArticleEuropean radiology2023

Advanced non-small-cell lung cancer treated with first-line pembrolizumab plus chemotherapy: tumor response dynamics as a marker for survival.

Mizuki Nishino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.